Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Former FDA Medical Policy Head Joins Greenleaf, Will Highlight FDA As “Resource”

Executive Summary

Rachel Sherman to expand drug capacity at FDA-centered consultancy, following 25 years at agency.

You may also be interested in...



Gottlieb Adds A No. 2: Sherman Is US FDA Principal Deputy Commissioner

Rachel Sherman takes over a position that has not been filled permanently since Josh Sharfstein left in 2011.

Finally … Rachel Sherman Takes Califf's Old FDA Job

After months of speculation, FDA veteran Rachel Sherman becomes deputy commissioner for medical products and tobacco.

Many Drug Approval Delays, Denials Could Be Prevented, FDA Study Shows

Agency reports preventable deficiencies, including failure to select optimal drug doses and suitable study endpoints, account for many drug rejections, approval delays.

Related Content

Topics

UsernamePublicRestriction

Register

PS056128

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel